Insights into wild-type and mutant p53 functions provided by genetically engineered mice

Human Mutation

Volumn 35, Issue 6, 2014, Pages 715-727

  Donehower, Lawrence A ^a  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

Genetically engineered mice; Mouse cancer models; P53; TP53; Trp53

Indexed keywords

MUTANT PROTEIN; PROTEIN P53;

ACETYLATION; ALLELE; APOPTOSIS; CANCER GROWTH; CANCER INHIBITION; CANCER SUSCEPTIBILITY; CARCINOGENESIS; CHROMOSOMAL INSTABILITY; DNA BINDING; DOUBLE STRANDED DNA BREAK; EMBRYONIC STEM CELL; GENE EXPRESSION; GENE INTERACTION; GENE TARGETING; GENETIC ENGINEERING; GENETICALLY ENGINEERED MOUSE STRAIN; GERMLINE MUTATION; HUMAN; MISSENSE MUTATION; NONHUMAN; NULL ALLELE; PHENOTYPE; POINT MUTATION; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; REVIEW; SOMATIC MUTATION; TRANSACTIVATION; TRANSCRIPTION INITIATION; TRANSGENE; TUMOR SUPPRESSOR GENE; WILD TYPE; ANIMAL; EXOME; GENETICS; HIGH THROUGHPUT SEQUENCING; MOUSE; NEOPLASM; PATHOLOGY; TRANSGENIC ANIMAL;

MUS;

ANIMALS; ANIMALS, GENETICALLY MODIFIED; EXOME; GERM-LINE MUTATION; HIGH-THROUGHPUT NUCLEOTIDE SEQUENCING; HUMANS; MICE; NEOPLASMS; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84901235131     PISSN: 10597794     EISSN: 10981004     Source Type: Journal    
DOI: 10.1002/humu.22507     Document Type: Review

References (109)

1. Adams CS, Horton WE Jr. 1998. Chondrocyte apoptosis increases with age in the articular cartilage of adult animals. Anat Rec 250:418-425.
2. Appella E, Anderson CW. 2001. Post-translational modifications and activation of p53 by genotoxic stresses. Eur J Biochem 268:2764-2772.
3. Armata HL, Garlick DS, Sluss HK. 2007. The ataxia telangiectasia-mutated target site Ser18 is required for p53-mediated tumor suppression. Cancer Res 67:11696-11703.
4. Armstrong JF, Kaufman MH, Harrison DJ, Clarke AR. 1995. High-frequency developmental abnormalities in p53-deficient mice. Curr Biol 5:931-936.
5. Artandi SE, DePinho RA. 2010. Telomeres and telomerase in cancer. Carcinogenesis 31:9-18.
6. Berger AH, Knudson AG, Pandolfi PP. 2011. A continuum model for tumour suppression. Nature 476:163-169.
7. Berman SD, Yuan TL, Miller ES, Lee EY, Caron A, Lees JA. 2008. The retinoblastoma protein tumor suppressor is important for appropriate osteoblast differentiation and bone development. Mol Cancer Res 6:1440-1451.
8. Brady CA, Jiang D, Mello SS, Johnson TM, Jarvis LA, Kozak MM, Kenzelmann Broz D, Basak S, Park EJ, McLaughlin ME, Karnezis AN, Attardi LD. 2011. Distinct p53 transcriptional programs dictate acute DNA-damage responses and tumor suppression. Cell 145:571-583.
9. Brooks CL, Gu W. 2011. The impact of acetylation and deacetylation on the p53 pathway. Protein Cell 2:456-462.
10. Brosh R, Rotter V. 2009. When mutants gain new powers: news from the mutant p53 field. Nat Rev Cancer 9:701-713.
11. Bruins W, Bruning O, Jonker MJ, Zwart E, van der Hoeven TV, Pennings JL, Rauwerda H, de Vries A, Breit TM. 2008. The absence of Ser389 phosphorylation in p53 affects the basal gene expression level of many p53-dependent genes and alters the biphasic response to UV exposure in mouse embryonic fibroblasts. Mol Cell Biol 28:1974-1987.
12. Bruins W, Jonker MJ, Bruning O, Pennings JL, Schaap MM, Hoogervorst EM, van Steeg H, Breit TM, de Vries A. 2007. Delayed expression of apoptotic and cell-cycle control genes in carcinogen-exposed bladders of mice lacking p53. S389 phosphorylation. Carcinogenesis 28:1814-1823.
13. Bruins W, Zwart E, Attardi LD, Iwakuma T, Hoogervorst EM, Beems RB, Miranda B, van Oostrom CT, van den Berg J, van den Aardweg GJ, Lozano G, van Steeg H, Jacks T, de Vries A. 2004. Increased sensitivity to UV radiation in mice with a p53 point mutation at Ser389. Mol Cell Biol 24:8884-8894.
14. Chao C, Herr D, Chun J, Xu Y. 2006. Ser18 and 23 phosphorylation is required for p53-dependent apoptosis and tumor suppression. EMBO J 25:2615-2622.
15. Choi J, Curtis SJ, Roy DM, Flesken-Nikitin A, Nikitin AY. 2010. Local mesenchymal stem/progenitor cells are a preferential target for initiation of adult soft tissue sarcomas associated with p53 and Rb deficiency. Am J Pathol 177:2645-2658.
16. Christophorou MA, Martin-Zanca D, Soucek L, Lawlor ER, Brown-Swigart L, Verschuren EW, Evan GI. 2005. Temporal dissection of p53 function in vitro and in vivo. Nat Genet 37:718-726.
17. Christophorou MA, Ringshausen I, Finch AJ, Swigart LB, Evan GI. 2006. The pathological response to DNA damage does not contribute to p53-mediated tumour suppression. Nature 443:214-217.
18. Donehower LA. 1996. The p53-deficient mouse: a model for basic and applied cancer studies. Semin Cancer Biol 7:269-278.
19. Donehower LA, Harvey M, Slagle BL, McArthur MJ, Montgomery CA Jr., Butel JS, Bradley A. 1992. Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumours. Nature 356:215-221.
20. Donehower LA, Harvey M, Vogel H, McArthur MJ, Montgomery CA Jr., Park SH, Thompson T, Ford RJ, Bradley A. 1995. Effects of genetic background on tumorigenesis in p53-deficient mice. Mol Carcinog 14:16-22.
21. Donehower LA, Lozano G. 2009. 20 years studying p53 functions in genetically engineered mice. Nat Rev Cancer 9:831-841.
22. Doyle B, Morton JP, Delaney DW, Ridgway RA, Wilkins JA, Sansom OJ. 2010. p53 mutation and loss have different effects on tumourigenesis in a novel mouse model of pleomorphic rhabdomyosarcoma. J Pathol 222:129-137.
23. Dumble M, Gatza C, Tyner S, Venkatachalam S, Donehower LA. 2004. Insights into aging obtained from p53 mutant mouse models. Ann N Y Acad Sci 1019:171-177.
24. Dumble M, Moore L, Chambers SM, Geiger H, Van Zant G, Goodell MA, Donehower LA. 2007. The impact of altered p53 dosage on hematopoietic stem cell dynamics during aging. Blood 109:1736-1742.
25. Feng L, Hollstein M, Xu Y. 2006. Ser46 phosphorylation regulates p53-dependent apoptosis and replicative senescence. Cell Cycle 5:2812-2819.
26. Feng L, Lin T, Uranishi H, Gu W, Xu Y. 2005a. Functional analysis of the roles of posttranslational modifications at the p53 C terminus in regulating p53 stability and activity. Mol Cell Biol 25:5389-5395.
27. Feng Z, Zhang H, Levine AJ, Jin S. 2005b. The coordinate regulation of the p53 and mTOR pathways in cells. Proc Natl Acad Sci USA 102:8204-8209.
28. Fishler T, Li YY, Wang RH, Kim HS, Sengupta K, Vassilopoulos A, Lahusen T, Xu X, Lee MH, Liu Q, Elledge SJ, Ried T, Deng CX. 2010. Genetic instability and mammary tumor formation in mice carrying mammary-specific disruption of Chk1 and p53. Oncogene 29:4007-4017.
29. Garcia-Cao I, Garcia-Cao M, Martin-Caballero J, Criado LM, Klatt P, Flores JM, Weill JC, Blasco MA, Serrano M. 2002. "Super p53" mice exhibit enhanced DNA damage response, are tumor resistant and age normally. EMBO J 21:6225-6235.
30. Ghebranious N, Sell S. 1998. Hepatitis B injury, male gender, aflatoxin, and p53 expression each contribute to hepatocarcinogenesis in transgenic mice. Hepatology 27:383-391.
31. Gillet R, Grimber G, Bennoun M, Caron de Fromentel C, Briand P, Joulin V. 2000. The consequence of p53 overexpression for liver tumor development and the response of transformed murine hepatocytes to genotoxic agents. Oncogene 19:3498-3507.
32. Godley LA, Kopp JB, Eckhaus M, Paglino JJ, Owens J, Varmus HE. 1996. Wild-type p53 transgenic mice exhibit altered differentiation of the ureteric bud and possess small kidneys. Genes Dev 10:836-850.
33. Harvey M, Vogel H, Lee EY, Bradley A, Donehower LA. 1995. Mice deficient in both p53 and Rb develop tumors primarily of endocrine origin. Cancer Res 55:1146-1151.
34. Hernandez I, Maddison LA, Wei Y, DeMayo F, Petras T, Li B, Gingrich JR, Rosen JM, Greenberg NM. 2003. Prostate-specific expression of p53(R172L) differentially regulates p21, Bax, and mdm2 to inhibit prostate cancer progression and prolong survival. Mol Cancer Res 1:1036-1047.
35. Hinkal G, Parikh N, Donehower LA. 2009. Timed somatic deletion of p53 in mice reveals age-associated differences in tumor progression. PLoS One 4:e6654.
36. Hinkal GW, Gatza, C.E., Parikh N, Donehower LA. 2009. Altered senescence, apoptosis, and DNA damage response in a mutant p53 model of accelerated aging. Mech Ageing Dev 130:262-271.
37. Hoogervorst EM, Bruins W, Zwart E, van Oostrom CT, van den Aardweg GJ, Beems RB, van den Berg J, Jacks T, van Steeg H, de Vries A. 2005. Lack of p53 Ser389 phosphorylation predisposses mice to develop 2-acetylaminofluorene-induced bladder tumors but not ionizing radiation-induced lymphomas. Cancer Res 65:3610-3616.
38. Jacks T, Remington L, Williams BO, Schmitt EM, Halachmi S, Bronson RT, Weinberg RA. 1994. Tumor spectrum analysis in p53-mutant mice. Curr Biol 4:1-7.
39. Jackson EL, Olive KP, Tuveson DA, Bronson R, Crowley D, Brown M, Jacks T. 2005. The differential effects of mutant p53 alleles on advanced murine lung cancer. Cancer Res 65:10280-10288.
40. Jackson JG, Lozano G. 2013. The mutant p53 mouse as a pre-clinical model. Oncogene 32:4325-4330.
41. Jenkins LM, Durell SR, Mazur SJ, Appella E. 2012. p53 N-terminal phosphorylation: a defining layer of complex regulation. Carcinogenesis 33:1441-1449.
42. Jiang D, Brady CA, Johnson TM, Lee EY, Park EJ, Scott MP, Attardi LD. 2011. Full p53 transcriptional activation potential is dispensable for tumor suppression in diverse lineages. Proc Natl Acad Sci USA 108:17123-17128.
43. Johnson TM, Hammond EM, Giaccia A, Attardi LD. 2005. The p53QS transactivation-deficient mutant shows stress-specific apoptotic activity and induces embryonic lethality. Nat Genet 37:145-152.
44. Jonkers J, Meuwissen R, van der Gulden H, Peterse H, van der Valk M, Berns A. 2001. Synergistic tumor suppressor activity of BRCA2 and p53 in a conditional mouse model for breast cancer. Nat Genet 29:418-425.
45. Kandoth C, Schultz N, Cherniack AD, Akbani R, Liu Y, Shen H, Robertson AG, Pashtan I, Shen R, Benz CC, Yau C, Laird PW, et al. 2013. Integrated genomic characterization of endometrial carcinoma. Nature 497:67-73.
46. Kenzelmann Broz D, Attardi LD. 2010. In vivo analysis of p53 tumor suppressor function using genetically engineered mouse models. Carcinogenesis 31:1311-1318.
47. Knudson AG Jr. 1971. Mutation and cancer: statistical study of retinoblastoma. Proc Natl Acad Sci USA 68:820-823.
48. Krummel KA, Lee CJ, Toledo F, Wahl GM. 2005. The C-terminal lysines fine-tune P53 stress responses in a mouse model but are not required for stability control or transactivation. Proc Natl Acad Sci USA 102:10188-10193.
49. Lang GA, Iwakuma T, Suh YA, Liu G, Rao VA, Parant JM, Valentin-Vega YA, Terzian T, Caldwell LC, Strong LC, El-Naggar AK, Lozano G. 2004. Gain of function of a p53 hot spot mutation in a mouse model of Li-Fraumeni syndrome. Cell 119:861-872.
50. Lavigueur A, Maltby V, Mock D, Rossant J, Pawson T, Bernstein A. 1989. High incidence of lung, bone, and lymphoid tumors in transgenic mice overexpressing mutant alleles of the p53 oncogene. Mol Cell Biol 9:3982-3991.
51. Lee MK, Tong WM, Wang ZQ, Sabapathy K. 2011. Serine 312 phosphorylation is dispensable for wild-type p53 functions in vivo. Cell Death Differ 18:214-221.
52. Levine AJ. 1997. p53, the cellular gatekeeper for growth and division. Cell 88:323-331.
53. Li T, Kon N, Jiang L, Tan M, Ludwig T, Zhao Y, Baer R, Gu W. 2012. Tumor suppression in the absence of p53-mediated cell-cycle arrest, apoptosis, and senescence. Cell 149:1269-1283.
54. Lin T, Chao C, Saito S, Mazur SJ, Murphy ME, Appella E, Xu Y. 2005. p53 induces differentiation of mouse embryonic stem cells by suppressing Nanog expression. Nat Cell Biol 7:165-171.
55. Liu D, Ou L, Clemenson GD Jr, Chao C, Lutske ME, Zambetti GP, Gage FH, Xu Y. 2010. Puma is required for p53-induced depletion of adult stem cells. Nat Cell Biol 12:993-998.
56. Liu G, McDonnell TJ, Montes de Oca Luna R, Kapoor M, Mims B, El-Naggar AK, Lozano G. 2000. High metastatic potential in mice inheriting a targeted p53 missense mutation. Proc Natl Acad Sci USA 97:4174-4179.
57. Liu G, Parant JM, Lang G, Chau P, Chavez-Reyes A, El-Naggar AK, Multani A, Chang S, Lozano G. 2004. Chromosome stability, in the absence of apoptosis, is critical for suppression of tumorigenesis in Trp53 mutant mice. Nat Genet 36:63-68.
58. Liu Z, Muehlbauer KR, Schmeiser HH, Hergenhahn M, Belharazem D, Hollstein MC. 2005. p53 mutations in benzo(a)pyrene-exposed human p53 knock-in murine fibroblasts correlate with p53 mutations in human lung tumors. Cancer Res 65:2583-2587.
59. Loughery J, Meek D. 2013. Switching on p53: an essential role for protein phosphorylation. Bio Discov 8:1-20.
60. Luo JL, Yang Q, Tong WM, Hergenhahn M, Wang ZQ, Hollstein M. 2001. Knock-in mice with a chimeric human/murine p53 gene develop normally and show wild-type p53 responses to DNA damaging agents: a new biomedical research tool. Oncogene 20:320-328.
61. MacDonald J, French JE, Gerson RJ, Goodman J, Inoue T, Jacobs A, Kasper P, Keller D, Lavin A, Long G, et al. 2004. The utility of genetically modified mouse assays for identifying human carcinogens: a basic understanding and path forward. The Alternatives to Carcinogenicity Testing Committee ILSI HESI. Toxicol Sci 77:188-194.
62. MacPherson D, Kim J, Kim T, Rhee BK, Van Oostrom CT, DiTullio RA, Venere M, Halazonetis TD, Bronson R, De Vries A, Fleming M, Jacks T. 2004. Defective apoptosis and B-cell lymphomas in mice with p53 point mutation at Ser 23. EMBO J 23:3689-3699.
63. Maier B, Gluba W, Bernier B, Turner T, Mohammad K, Guise T, Sutherland A, Thorner M, Scrable H. 2004. Modulation of mammalian life span by the short isoform of p53. Genes Dev 18:306-319.
64. Malkin D. 2011. Li-Fraumeni syndrome. Genes Cancer 2:475-484.
65. Malkin D, Li FP, Strong LC, Fraumeni JF Jr, Nelson CE, Kim DH, Kassel J, Gryka MA, Bischoff FZ, Tainsky MA. 1990. Germ line p53 mutations in a familial syndrome of breast cancer, sarcomas, and other neoplasms. Science 250:1233-1238.
66. Marino S, Vooijs M, van Der Gulden H, Jonkers J, Berns A. 2000. Induction of medulloblastomas in p53-null mutant mice by somatic inactivation of Rb in the external granular layer cells of the cerebellum. Genes Dev 14:994-1004.
67. Martinez-Cruz AB, Santos M, Lara MF, Segrelles C, Ruiz S, Moral M, Lorz C, Garcia-Escudero R, Paramio JM. 2008. Spontaneous squamous cell carcinoma induced by the somatic inactivation of retinoblastoma and Trp53 tumor suppressors. Cancer Res 68:683-692.
68. Martins CP, Brown-Swigart L, Evan GI. 2006. Modeling the therapeutic efficacy of p53 restoration in tumors. Cell 127:1323-1334.
69. Matheu A, Maraver A, Klatt P, Flores I, Garcia-Cao I, Borras C, Flores JM, Vina J, Blasco MA, Serrano M. 2007. Delayed ageing through damage protection by the Arf/p53 pathway. Nature 448:375-379.
70. Monahan KB, Rozenberg GI, Krishnamurthy J, Johnson SM, Liu W, Bradford MK, Horner J, Depinho RA, Sharpless NE. 2010. Somatic p16(INK4a) loss accelerates melanomagenesis. Oncogene 29:5809-5817.
71. Moore L, Lu X, Ghebranious N, Tyner S, Donehower LA. 2007. Aging-associated truncated form of p53 interacts with wild-type p53 and alters p53 stability, localization, and activity. Mech Ageing Dev 128:717-730.
72. Nicol CJ, Harrison ML, Laposa RR, Gimelshtein IL, Wells PG. 1995. A teratologic suppressor role for p53 in benzo[a]pyrene-treated transgenic p53-deficient mice. Nat Genet 10:181-187.
73. Nister M, Tang M, Zhang XQ, Yin C, Beeche M, Hu X, Enblad G, van Dyke T, Wahl GM. 2005. p53 must be competent for transcriptional regulation to suppress tumor formation. Oncogene 24:3563-3573.
74. Olive KP, Tuveson DA, Ruhe ZC, Yin B, Willis NA, Bronson RT, Crowley D, Jacks T. 2004. Mutant p53 gain of function in two mouse models of Li-Fraumeni syndrome. Cell 119:847-860.
75. Petitjean A, Achatz MI, Borresen-Dale AL, Hainaut P, Olivier M. 2007. TP53 mutations in human cancers: functional selection and impact on cancer prognosis and outcomes. Oncogene 26:2157-2165.
76. Pritchard JB, French JE, Davis BJ, Haseman JK. 2003. The role of transgenic mouse models in carcinogen identification. Environ Health Perspect 111:444-454.
77. Purdie CA, Harrison DJ, Peter A, Dobbie L, White S, Howie SE, Salter DM, Bird CC, Wyllie AH, Hooper ML, Clarke AR. 1994. Tumour incidence, spectrum and ploidy in mice with a large deletion in the p53 gene. Oncogene 9:603-609.
78. Quinn BA, Brake T, Hua X, Baxter-Jones K, Litwin S, Ellenson LH, Connolly DC. 2009. Induction of ovarian leiomyosarcomas in mice by conditional inactivation of Brca1 and p53. PloS One 4:e8404.
79. Regeling A, Armata HL, Gallant J, Jones SN, Sluss HK. 2011. Mice defective in p53 nuclear localization signal 1 exhibit exencephaly. Trans Res 20:899-912.
80. Serrano M, Blasco MA. 2007. Cancer and ageing: convergent and divergent mechanisms. Nat Rev Mol Cell Biol 8:715-722.
81. Shiloh Y, Ziv Y. 2013. The ATM protein kinase: regulating the cellular response to genotoxic stress, and more. Nat Rev Mol Cell Biol 14:197-210.
82. Shimada S, Mimata A, Sekine M, Mogushi K, Akiyama Y, Fukamachi H, Jonkers J, Tanaka H, Eishi Y, Yuasa Y. 2012. Synergistic tumour suppressor activity of E-cadherin and p53 in a conditional mouse model for metastatic diffuse-type gastric cancer. Gut 61:344-353.
83. Slee EA, Benassi B, Goldin R, Zhong S, Ratnayaka I, Blandino G, Lu X. 2010. Phosphorylation of Ser312 contributes to tumor suppression by p53 in vivo. Proc Natl Acad Sci USA 107:19479-19484.
84. Sluss HK, Armata H, Gallant J, Jones SN. 2004. Phosphorylation of serine 18 regulates distinct p53 functions in mice. Mol Cell Biol 24:976-984.
85. Sluss HK, Gannon H, Coles AH, Shen Q, Eischen CM, Jones SN. 2010. Phosphorylation of p53 serine 18 upregulates apoptosis to suppress Myc-induced tumorigenesis. Mol Cancer Res 8:216-222.
86. Song H, Hollstein M, Xu Y. 2007. p53 gain-of-function cancer mutants induce genetic instability by inactivating ATM. Nat Cell Biol 9:573-580.
87. Soussi T. 2011. TP53 mutations in human cancer: database reassessment and prospects for the next decade. Adv Cancer Res 110:107-139.
88. The Cancer Genome Atlas Research Network. 2008. Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature 455:1061-1068.
89. The Cancer Genome Atlas Research Network (TCGA). 2011. Integrated genomic analyses of ovarian carcinoma. Nature 474:609-615.
90. The Cancer Genome Atlas Research Network (TCGA). 2012a. Comprehensive molecular portraits of human breast tumours. Nature 490:61-70.
91. The Cancer Genome Atlas Research Network (TCGA). 2012b. Comprehensive molecular characterization of human colon and rectal cancer. Nature 487:330-337.
92. The Cancer Genome Atlas Research Network (TCGA). 2012c. Comprehensive genomic characterization of squamous cell lung cancers. Nature 489:519-525.
93. Timofeev O, Schlereth K, Wanzel M, Braun A, Niewsandt B, Pagenstecher A, Rosenwald A, Elsasser H-P, Stiewe T. 2013. p53 DNA binding cooperativity is essential for apoptosis and tumor suppression in vivo. Cell Rep 5:1512-1525.
94. Toledo F, Krummel KA, Lee CJ, Liu CW, Rodewald LW, Tang M, Wahl GM. 2006. A mouse p53 mutant lacking the proline-rich domain rescues Mdm4 deficiency and provides insight into the Mdm2-Mdm4-p53 regulatory network. Cancer Cell 9:273-285.
95. Toledo F, Lee CJ, Krummel KA, Rodewald LW, Liu CW, Wahl GM. 2007. Mouse mutants reveal that putative protein interaction sites in the p53 proline-rich domain are dispensable for tumor suppression. Mol Cell Biol 27:1425-1432.
96. Tomas-Loba A, Flores I, Fernandez-Marcos PJ, Cayuela ML, Maraver A, Tejera A, Borras C, Matheu A, Klatt P, Flores JM, Viña J, Serrano M, Blasco MA. 2008. Telomerase reverse transcriptase delays aging in cancer-resistant mice. Cell 135:609-622.
97. Tonks ID, Mould AW, Schroder WA, Cotterill A, Hayward NK, Walker GJ, Kay GF. 2010. Dual loss of rb1 and Trp53 in the adrenal medulla leads to spontaneous pheochromocytoma. Neoplasia 12:235-243.
98. Tsukada T, Tomooka Y, Takai S, Ueda Y, Nishikawa S, Yagi T, Tokunaga T, Takeda N, Suda Y, Abe S, Matsuo I, Ikawa Y, Aizawa S. 1993. Enhanced proliferative potential in culture of cells from p53-deficient mice. Oncogene 8:3313-3322.
99. Tyner SD, Venkatachalam S, Choi J, Jones S, Ghebranious N, Igelmann H, Lu X, Soron G, Cooper B, Brayton C, Park SH, Thompson T, Karsenty, G, Bradley A, Donehower LA. 2002. p53 mutant mice that display early ageing-associated phenotypes. Nature 415:45-53.
100. Ventura A, Kirsch DG, McLaughlin ME, Tuveson DA, Grimm J, Lintault L, Newman J, Reczek EE, Weissleder R, Jacks T. 2007. Restoration of p53 function leads to tumour regression in vivo. Nature 445:661-665.
101. Vousden KH, Lu X. 2002. Live or let die: the cell's response to p53. Nat Rev Cancer 2:594-604.
102. Vousden KH, Prives C. 2009. Blinded by the light: the growing complexity of p53. Cell 137:413-431.
103. Walker KK, Levine AJ. 1996. Identification of a novel p53 functional domain that is necessary for efficient growth suppression. Proc Natl Acad Sci USA 93:15335-15340.
104. Wang XJ, Greenhalgh DA, Jiang A, He D, Zhong L, Medina D, Brinkley BR, Roop DR. 1998. Expression of a p53 mutant in the epidermis of transgenic mice accelerates chemical carcinogenesis. Oncogene 17:35-45.
105. Wei QX, Odell AF, van der Hoeven F, Hollstein M. 2011. Rapid derivation of genetically related mutants from embryonic cells harboring a recombinase-specific Trp53 platform. Cell Cycle 10:1261-1270.
106. Wei QX, van der Hoeven F, Hollstein M, Odell AF. 2012. Efficient introduction of specific TP53 mutations into mouse embryonic fibroblasts and embryonic stem cells. Nat Protoc 17:1145-1160.
107. Wijnhoven SW, Zwart E, Speksnijder EN, Beems RB, Olive KP, Tuveson DA, Jonkers J, Schaap MM, van den Berg J, Jacks T, van Steeq H, de Vries A. 2005. Mice expressing a mammary gland-specific R270H mutation in the p53 tumor suppressor gene mimic human breast cancer development. Cancer Res 65:8166-8173.
108. Williams BO, Remington L, Albert DM, Mukai S, Bronson RT, Jacks T. 1994. Cooperative tumorigenic effects of germline mutations in Rb and p53. Nat Genet 7:480-484.
109. Zindy F, Uziel T, Ayrault O, Calabrese C, Valentine M, Rehg JE, Gilbertson RJ, Sherr CJ, Roussel MF. 2007. Genetic alterations in mouse medulloblastomas and generation of tumors de novo from primary cerebellar granule neuron precursors. Cancer Res 67:2676-2684.